Novo Nordisk A/S (NVO) : The consensus on Novo Nordisk A/S (NVO) based on 3 analyst recommendation on the company stock is 3, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Company shares have received an average consensus rating of Hold for the current week Also, Equity Analysts at the HSBC upgrades the rating on Novo Nordisk A/S (NYSE:NVO). The brokerage firm has issued a Hold rating on the shares. The shares were previously rated Reduce. The rating by the firm was issued on August 31, 2016.
Novo Nordisk A/S (NYSE:NVO): stock was range-bound between the intraday low of $45.56 and the intraday high of $46.005 after having opened at $45.58 on Wednesdays session. The stock finally closed in the red at $45.58, a loss of -0.24%. The stock remained in the red for the whole trading day. The total traded volume was 3,252,290 shares. The stock failed to cross $46.005 in Wednesdays trading. The stocks closing price on Thursday was $46.
Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Companys diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark, and internationally in the United States, France, China and Brazil.